SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly period ended June 30, 2002, and the six months ended June 30, 2002. The company operates in three primary segments: Life Sciences, Optoelectronics, and Analytical Instruments. The period was marked by significant strategic shifts, including the adoption of new accounting standards (SFAS No. 142), the acquisition of Packard BioScience, and the divestiture of several business units classified as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 |
Three Months Ended July 1, 2001 |
Six Months Ended June 30, 2002 |
Six Months Ended July 1, 2001 |
|---|---|---|---|---|
| Sales (Continuing Ops) | $335.7 million | $321.4 million | $637.3 million | $642.4 million |
| Operating Income (Loss) | $12.2 million | $35.8 million | ($7.5 million) | $66.5 million |
| Net Income (Loss) | ($9.1 million) | $29.4 million | ($156.5 million) | $52.9 million |
| EPS (Diluted) | ($0.07) | $0.28 | ($1.25) | $0.51 |
| Cash and Equivalents | $143.3 million | $138.3 million (Dec 30, 2001) | Balance Sheet Data | |
| Total Debt (Short + Long) | $706.4 million | $723.9 million (Dec 30, 2001) | Balance Sheet Data | |
| Operating Cash Flow | N/A (Quarterly) | ($26.6 million) | $6.2 million |
Note: Net loss for the six months ended June 30, 2002, includes a $117.8 million charge for goodwill impairment (effect of accounting change) and a $3.6 million extraordinary loss on debt redemption.
Material Changes vs. Prior Period
- Revenue: Sales for the quarter increased 4% year-over-year, driven by the inclusion of the Packard BioScience acquisition and favorable foreign exchange. However, organic revenue declined 6% due to weakness in Optoelectronics and Analytical Instruments.
- Profitability: Operating income from continuing operations dropped significantly from $35.8 million in Q2 2001 to $12.2 million in Q2 2002. The six-month period swung from a $66.5 million profit to a $7.5 million loss.
- Accounting Changes: The company adopted SFAS No. 142, ceasing goodwill amortization but requiring impairment testing. This resulted in a one-time $117.8 million impairment charge related to the lighting reporting unit within Optoelectronics.
- Discontinued Operations: The company sold its Security and Detection Systems business for approximately $100 million. It also ceased operations in Telecom Components and approved the disposal of Entertainment Lighting and Fluid Sciences, recording significant losses on dispositions.
- Restructuring: The company recorded $9.2 million in restructuring charges in the first quarter of 2002 related to workforce reductions and facility closures.
Guidance, Outlook, and Risks
- Liquidity and Debt Covenants: The company faces a critical risk regarding its ability to comply with the Interest Coverage covenant in its credit agreements by the end of the third quarter (September 30, 2002). Failure to comply could trigger a default, accelerating debt obligations totaling approximately $150 million.
- Financing Strategy: If waivers are not obtained, the company plans to repay and terminate its credit facilities and a specific lease to avoid default. Management believes current cash ($170 million as of August 12, 2002) is sufficient to fund this repayment but notes uncertainty in obtaining new financing if required.
- Market Conditions: Operating results are negatively impacted by cyclical downturns in the telecom, pharmaceutical, and photography markets, leading to reduced demand and pricing pressure.
- Legal Proceedings: The company is facing multiple class-action lawsuits alleging misleading statements regarding prospects and operating results. Additionally, the company dismissed Arthur Andersen LLP as its auditor in June 2002 and engaged Deloitte & Touche LLP.
Key Facts for Investor Verification
- Covenant Compliance: Verify the status of negotiations with lenders regarding the Interest Coverage covenant waiver for the quarter ending September 30, 2002.
- Goodwill Impairment: Confirm the valuation methodology used for the $117.8 million impairment charge and assess the risk of future impairments under SFAS No. 142.
- Discontinued Operations: Monitor the progress of the sale of the Fluid Sciences business and the final net proceeds from the Security and Detection Systems sale.
- Organic Growth: Analyze the 6-7% decline in organic revenue to determine if the weakness in Optoelectronics and Analytical Instruments is a temporary cyclical issue or a structural decline.
- Debt Rating: Assess the impact of the recent debt rating downgrade on the company's ability to access commercial paper markets and future borrowing costs.